Enzychem Lifesciences Corporation (183490.KQ)
KRW 1080.0
(0.19%)
KRW 1080.0
(0.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 18.7 Billion KRW | 9.78% |
| 2022 | 16.42 Billion KRW | -19.41% |
| 2021 | 20.37 Billion KRW | 6.39% |
| 2020 | 19.15 Billion KRW | 3.39% |
| 2019 | 18.52 Billion KRW | -1.57% |
| 2018 | 18.82 Billion KRW | 110.38% |
| 2017 | 8.94 Billion KRW | -2.84% |
| 2016 | 9.2 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.76 Billion KRW | -18.06% |
| 2024 Q2 | 4.67 Billion KRW | 24.29% |
| 2023 Q4 | 4.58 Billion KRW | -3.67% |
| 2023 Q1 | 4.19 Billion KRW | -2.05% |
| 2023 Q2 | 4.47 Billion KRW | 6.66% |
| 2023 FY | 18.02 Billion KRW | 9.78% |
| 2023 Q3 | 4.76 Billion KRW | 6.39% |
| 2022 Q2 | 3.99 Billion KRW | -18.13% |
| 2022 FY | 16.42 Billion KRW | -19.41% |
| 2022 Q4 | 4.28 Billion KRW | 33.91% |
| 2022 Q3 | 3.2 Billion KRW | -19.96% |
| 2022 Q1 | 4.88 Billion KRW | -3.41% |
| 2021 Q1 | 6.3 Billion KRW | 25.12% |
| 2021 FY | 20.37 Billion KRW | 6.39% |
| 2021 Q4 | 5.05 Billion KRW | 1.04% |
| 2021 Q3 | 5 Billion KRW | 17.82% |
| 2021 Q2 | 4.24 Billion KRW | -32.63% |
| 2020 Q4 | 5.03 Billion KRW | -12.74% |
| 2020 Q3 | 5.77 Billion KRW | 43.05% |
| 2020 Q1 | 5.32 Billion KRW | -13.98% |
| 2020 Q2 | 4.03 Billion KRW | -24.2% |
| 2020 FY | 19.15 Billion KRW | 3.39% |
| 2019 Q3 | 3.12 Billion KRW | -51.97% |
| 2019 Q1 | 4.15 Billion KRW | 8.84% |
| 2019 FY | 18.52 Billion KRW | -1.57% |
| 2019 Q4 | 6.19 Billion KRW | 98.12% |
| 2019 Q2 | 6.5 Billion KRW | 56.44% |
| 2018 FY | 18.82 Billion KRW | 110.38% |
| 2018 Q2 | 3.81 Billion KRW | -46.7% |
| 2018 Q4 | 3.82 Billion KRW | -4.76% |
| 2018 Q3 | 4.01 Billion KRW | 5.15% |
| 2018 Q1 | 7.15 Billion KRW | 219.55% |
| 2017 Q2 | 2.5 Billion KRW | 0.0% |
| 2017 FY | 8.94 Billion KRW | -2.84% |
| 2017 Q3 | 2.48 Billion KRW | -0.76% |
| 2017 Q4 | 2.24 Billion KRW | -9.77% |
| 2016 FY | 9.2 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 81.757% |
| CMG Pharmaceutical Co., Ltd. | 37.86 Billion KRW | 50.605% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | 76.89% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 93.657% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 94.469% |
| Humedix Co., Ltd. | 33.04 Billion KRW | 43.395% |
| Boditech Med Inc. | 47.05 Billion KRW | 60.248% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | 25.063% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -104.058% |
| Huons Co., Ltd. | 226.14 Billion KRW | 91.729% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | 25.774% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -13.69% |